Diabetes Management Tablet in pharma franchise in Uttar Pradesh

Diabetes Management Tablet in PCD pharma franchise in Dispur

Diabetes Management Tablet in top pharma company in Ahmedabad

Diabetes Management Tablet in pcd pharma supplier in Jaipur

Diabetes Management Tablet in phama franchise company in India
Diabetes Management Tablet in phama distributor in Lucknow

Home/Products /empagliflozin-10mg-sitagliptin-100mg-metformin-1000mg-extended-release-tablet

About the Product

Description


Emplozin SM 10 Tablet is a combination medication used in the management of Type 2 diabetes mellitus in adults. This tablet combines three active ingredients: Empagliflozin, Sitagliptin, and Metformin, each of which plays a unique role in regulating blood glucose levels.

  • Empagliflozin (10mg) is an SGLT2 inhibitor that works by preventing the reabsorption of glucose by the kidneys, which allows more glucose to be excreted in the urine, thereby lowering blood sugar levels.
  • Sitagliptin (100mg) is a DPP-4 inhibitor that increases the amount of insulin released by the pancreas in response to meals, while decreasing the release of glucagon, a hormone that raises blood sugar.
  • Metformin (1000mg) is a biguanide that works by decreasing the amount of sugar produced by the liver and improving the body’s sensitivity to insulin. The extended-release formulation of Metformin helps reduce gastrointestinal side effects while providing sustained blood glucose control.

This combination tablet is intended for patients with Type 2 diabetes who have not achieved adequate blood glucose control with diet and exercise alone or with other oral medications. Emplozin SM 10 Tablet is used to improve glycemic control in combination with a proper diet and exercise regimen.

The synergistic action of these three drugs helps in reducing both fasting and postprandial blood sugar levels, improving overall diabetes management and reducing the risk of complications associated with the disease.

Common side effects may include nausea, headache, abdominal discomfort, and dizziness. Serious side effects may include low blood sugar (especially when combined with other anti-diabetic drugs), lactic acidosis, or kidney problems.

For the treatment of Type 2 diabetes mellitus in adults to improve blood glucose control, in combination with diet and exercise.

Not recommended for patients with severe kidney disease or diabetic ketoacidosis. Regular kidney function monitoring is advised during treatment.

Store at room temperature in a cool, dry place, away from direct sunlight. Keep out of the reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Empagliflozin 10mg + Sitagliptin 100mg + Metformin 1000mg Extended Release Tablet in the PCD pharma franchise market?

This advanced triple-combination anti-diabetic formulation is widely used in type 2 diabetes management, making it a high-demand prescription product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.

Why should medical distributors include this tablet in their product range?

Medical distributors and wholesalers can benefit from consistent demand in type 2 diabetes, blood sugar control, insulin resistance management, cardiovascular risk reduction support, and long-term glycemic management. The extended-release formulation helps improve patient compliance and is commonly prescribed by diabetologists and physicians for comprehensive diabetes care.

Does Cafoli Lifecare offer PCD pharma franchise opportunities for this product?

Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Empagliflozin 10mg + Sitagliptin 100mg + Metformin 1000mg Extended Release Tablets with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.

What benefits do wholesalers get by partnering for this anti-diabetic product?

Wholesalers and medical agencies benefit from strong chronic prescription demand, growing diabetic patient populations, repeat monthly therapy usage, and high acceptance in diabetology segments when partnering with Cafoli Lifecare.

How can I become a distributor or franchise partner for this tablet?

Medical distributors, stockists, wholesalers, and pharma professionals interested in this anti-diabetic formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.